Abstract: Novel diketoacid compounds of Formula I are provided which are useful as HIV integrase inhibitors and for the treatment of AIDS or ARC.

Abstract: The present invention concerns the use of compounds of the Formula (I) for treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and/or secondary inflammatory osteoarthritic pain. The compounds show an antinociceptive profile and differ from classical analgesics like opioids and non-steroidal anti-inflammatory drugs (NSAIDS) and are useful as specific analgesics.

Abstract: This invention relates to a process for the preparation of alkyl-N-(3-dimethylamino)alkylcarbarnates by reacting an alkyl-chloroformate in an alcohol.

Abstract: The present invention provides a method for preparing S-aryl cysteine. Specifically, the present invention provides enantioselective method for preparing S-aryl cysteine starting from cystine, cysteine or serine amino acid. The methods of the present invention provides S-aryl cysteine in enantiomeric excess of greater than about 96%.

Abstract: The present invention relates to a process for the dissociation of allophanates, in which a thermal dissociation is carried out in a reaction vessel and the gaseous dissociation products obtained are removed from the reaction vessel using an inert carrier gas or the vapor of a liquid as stripping medium and are condensed.

Abstract: The invention concerns the use as catalyst for transforming carbamates of compounds corresponding to the general formula (I): —Sn (X) (X′) wherein: X′ is selected among chloride, bromide, iodide, thiocyanate radicals, sulphonate radicals, advantageously perfluorinated on the carbon bearing the sulphonate function; X is selected among the values of X′ and among radicals of formula Y-Z; Y is selected among the chalcogen groups, advantageously light (that is oxygen and sulphur); Z is selected in the group consisting of trisubstituted tin, monosubstituted zinc, and the oxygenated acid radicals after ignoring the OH function. The invention is applicable to the coating industry.

Abstract: Phase change ink carrier compositions comprising an admixture of (1) at least one urethane resin; and/or (2) at least one mixed urethane/urea resin; and/or (3) at least one mono-amide; and/or (4) at least one polyethylene wax are provided. In addition, a phase change colored ink of such carrier compositions comprising a phase change ink compatible colorant are also provided. Embodiments of the present invention also include methods for producing a layer of the above phase change colored ink on the surface of a substrate by either direct or indirect printing. Such methods also encompassing using a polyethylene wax as an overcoat layer above such a phase change ink layer on a printed substrate.

Abstract: The end-blocked isocyanate prepolymer having an oxadiazine ring according to the present invention is characterized in that at least one of isocyanate groups of a NCO-terminated isocyanate prepolymer, which has NCO groups at the ends and comprises units derived from an oxadiazinetrione compound (A) represented by the following formula (1) and units derived from an active hydrogen compound (B) represented by the following formula (2), is blocked with a unit derived from an end-blocking agent (C) having at least one active hydrogen in one molecule, and that the end-blocked isocyanate prepolymer has a softening point of not lower than 50° C.

Abstract: The present invention is directed to new compositions of matter comprising the reaction products of a carboxylic acid and a urea having the formula: where R1, R2, R3 and R4 are the same or different and are selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, allyl, vinyl and alkoxyl groups having from 1-6 carbon atoms, substituted and unsubstituted phenyl groups and the halides. Preferably, the reaction product of the present invention is N,N′-diformylurea or N,N′-diacetylurea. These reaction products, e.g., diformylurea, have been found to produce significantly improved growth in a variety of agricultural products when applied to the seed, to the surrounding soil or to the foliage of the emerging plant. Because of the similarity in the carbon, nitrogen, oxygen structure of these reaction products with many biological compounds, it is believed that the reaction products of the present invention may find use in a variety of biological applications.

Abstract: A method of preparing hydroxyalkylcarbamates from six-membered cyclic carbonates. The method involves reacting a six-membered cyclic carbonate with anhydrous ammonia or aqueous ammonium hydroxide. The present invention also provides for hydroxyalkylcarbamates prepared from six-membered cyclic carbonates, and for coating compositions comprising hydroxyalkylcarbamates prepared according to the present invention.

Abstract: GABA-related pro-drugs of the formula (III) are provided that when administered to humans or other mammals provide an increased duration of active compound in the plasma compared to compounds of corresponding structure in which labile groups are not present. The compounds are of the formula (III) In the above formula: P represents hydrogen or methyl; Q represents a labile amine- or amide-forming organic group that becomes removed in the human or animal body; R1 represents straight or branched C2-C6 alkyl, C3-C6 cycloalkyl or phenyl; R2 represents hydrogen or methyl; and R3 represents hydrogen, methyl or carboxyl; and R4 represents hydrogen or a labile ester-forming group selected from substituted and unsubstituted C1-C6 alkyl, benzyl and phenyl groups that become removed in the human or animal body. In the above formula when R1 is phenyl, R2, R3 and R4 are not simultaneously hydrogen.

Abstract: The invention concerns a novel catalyst for forming urethanes. Said catalyst is characterized by the general formula: MY3−q[Z]q, wherein: Z is the radical corresponding to the anion of a super acid whereof the Hamett constant is at least equal to 13 and advantageously more than 13, M representing a trivalent metal, preferably known for forming Lewis acids; Y is an anion or a monovalent anionic function; and q is an integer selected advantageously between 1 and 3, inclusively. The invention is applicable to paint.

Abstract: A method of preparing UV-curable urethane compositions is disclosed. The method comprises two steps. First, isophorone diisocyanate (IPDI) reacts with a hydroxy-functional resin to form an NCO prepolymer. Second, the NCO prepolymer reacts with a hydroxy-functional ethylenic monomer to form the UV-curable urethane composition. The hydroxy-functional resin comprises at least about 2 wt % of recurring units of a propoxylated allylic alcohol. The method of the invention allows the preparation of UV-curable urethane compositions from acrylic polyols without gel.

Abstract: In accordance with the present invention, there are provided thermosetting resin compositions with a reduced propensity to shrink in volume upon cure and methods of use therefor. The compositions of the present invention include compounds having aromatic, rigid-rod like spacer groups between the crosslinkable moieties. As such, these compounds impart a degree of liquid crystal-like character to the thermosetting resin composition which results in lower shrinkage upon cure. This effect follows from the well-known expansion that occurs when liquid crystal-like materials pass from a nematic liquid crystal-like state to an isotropic state. Further provided by the present invention are low shrinkage die attach pastes and methods of use therefor.

Abstract: The invention relates to a compound comprising a reaction product of (A) an isocyanate functional compound of which at least 40 wt. %, relative to the total amount of (A), has a molecular weight of at least about 500, and (B) a nitrogen-containing compound capable of reacting with said isocyanate functional compound (A). The reaction product has a molecular weight of less then about 20,000 and comprises an effective amount of groups that are able to form reversible intermolecular physical interactions such that a resulting compound shows polymeric mechanical properties at a temperature below a transition temperature. The nitrogen-containing compound is, for instance, melamine, urea, acetoguanamine, benzoguanamine, cyanamide, dicyanamide, thiourea, isocytosine, pyrimidone or aminopyridine. The supramolecular compound comprising a suitable amount of the reaction products exhibits a relatively high elongation at break.

Abstract: Adamantane derivatives in which two (meth)acryloyloxyalkyl groups are bonded with an adamantane ring through ester groups, adamantane derivatives in which two adamantane rings are bonded through an alkylene group and two urethane bonds, which two adamantane rings each have a (meth)acryloyloxy group bonded thereto directly or through a coupling group, and adamantane derivatives each having a structure in which a group containing an adamantane ring hangs on the alkylene group of an alkylene glycol di(meth)acrylate. The compounds are useful as dental materials intermediates therefor, and as intermediates for optical materials such as lenses.

Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: The invention provides processes for preparing N-protected &bgr;-amino aldehyde compounds which are useful as synthetic intermediates for preparing glycopeptide antibiotic derivatives. The processes include cleaving a carbon-carbon double bond to form the N-protected &bgr;-amino aldehyde compound.

Abstract: A therapeutic formulation comprising a microemulsion of a therapeutic agent in free and/or conjugatively coupled form, wherein the microemulsion comprises a water-in-oil (w/o) microemulsion including a lipophilic phase and a hydrophilic phase, and has a hydrophilic and lipophilic balance (HLB) value between 3 and 7, wherein the therapeutic agent may for example be selected from the group consisting of insulin, calcitonin, ACTH, glucagon, somatostatin, somatotropin, somatomedin, parathyroid hormone, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, non-naturally occurring opioids, superoxide dismutase, interferon, asparaginase, arginase, arginine deaminease, adenosine deaminase, ribonuclease, trypsin, chymotrypsin, papain, Ara-A (Arabinofuranosyladenine), Acylguanosine, Nordeoxyguanosine, Azidothymidine, Didesoxyadenosine, Dideoxycytidine, Dideoxyinosine Floxuridine, 6-Mercaptopurine, Doxorubicin, Daunorubicin, or I-darubicin, Erythro

Abstract: the present invention provides novel compounds represented by formula I: 1

Abstract: A process for producing &agr;-amino-dihalogenated methyl ketone derivatives by reacting an N-protected &agr;-amino acid ester with a dihalomethyl lithium is provided. This process is suitable for the production on an industrial scale and by this process, &agr;-amino-dihalogenated methyl ketone derivatives and &bgr;-amino-&agr;-hydroxycarboxylic acid derivatives can be obtained efficiently and economically advantageously.

Abstract: Resins and waxes made by reacting selected nucleophiles, including alcohols and/or amines, with an isocyanate are disclosed. The order of addition of the isocyanate and the different nucleophiles can tailor the distribution of di-urethane, mixed urethane/urea, and/or di-urea molecules in the final resin product. The isocyanate-derived resin and wax materials are useful as ingredients as phase change ink carrier compositions used to make phase change ink jet inks.

Abstract: A compound of general formula (I) wherein R1 and R2 are H, C1-C6alkyl or (CH2)d(C3-C6cycloalkyl) wherein d=0, 1, 2 or 3; or R1 and R2 together with the nitrogen to which they are attached form an azetidine ring; Z or Y is —SR3 and the other Z or Y is halogen or —R3; wherein R3 is C1-C4 alkyl optionally substituted with fluorine; except that R3 is not CF3; or Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5 to 7-membered carbocyclic or heterocyclic ring, and wherein when Z and Y form a heterocyclic ring, in addition to carbon atoms, the linkage contains one or two heteroatoms independently selected from oxygen, sulfur and nitrogen; R4 and R5, which may be the same or different, are: A—X, wherein A=—CH═CH— or —(CH2)p— where p is 0, 1 or 2; X is hydrogen, F, Cl, Br, I, CONR6R7, SO2NR6R7, SO2NHC(═O)R6, OH, C1-4alkoxy, NR8SO2R9, NO2, NR6R11, CN, CO2R10, CHO, SR10, S(O)R9 or SO2R10; or a 5- or 6-membered het

Abstract: A process is described for the preparation of R or S aminocarnitine, R or S phosphonium aminocarnitine and R and S 3,4 diaminobutanoic acid, and their derivatives with the following formula: 1

Abstract: Novel monofunctional polyethylene glycol aldehyde for pegylating therapeutically active proteins to produce pegylated protein conjugates which retain a substantial portion of their therapeutic activity and are less immunogenic than the protein from which the conjugate is derived and a new synthesis for preparing such aldehydes.

Abstract: A method of preparing a pyrrolotriazin-4-one and a method of preparing the isothiocyanatoformic acid ester derivative which can be used as a reactant in that method of preparing a pyrrolotriazin-4-one. The method of preparing the pyrrolotriazin-4-one includes an addition step of an aminopyrrole derivative and the isothiocyanatoformic compound and a step of ring-closing reaction of a resulting adduct.

Abstract: The present invention relates to compounds of formula (I): 1

Abstract: The decomposition of di-t-butyl dicarbonate which is a thermally unstable compound is inhibited. To achieve the object, a hydrocarbon compound such as hexane, cyclohexane, 1-hexene or toluene and/or a chain ether compound such as diisopropyl ether or t-butyl methyl ether are/is used as a decomposition inhibitor for di-t-butyl dicarbonate.

Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Abstract: Disclosed are biological reagents which comprise compounds that inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in determining the cellular mechanism involved in the generation of &bgr;-amyloid peptide.

Abstract: The invention provides conjugates of fatty amines and pharmaceutical agents useful in treating cancer, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparations of the fatty amine-pharmaceutical agent conjugates are provided.

Abstract: The process disclosed herein satisfies the need in the art for an industrially viable oxidative carbonylation catalytic system, and is capable of producing carbamates at a significantly higher rate than those processes reported in journal and patent literature. This reaction process takes place via a reaction mechanism that does not involve drastic conditions. Specifically, the catalytic system of the present invention employs Group VIII metal catalysts and/or copper-based catalysts with halide promoters to produce carbamates through heterogeneous oxidative carbonylation at atmospheric pressure and relatively non-drastic temperatures in a gas-solid carbonylation process.

Abstract: A method of preparing a carbamate or urea-functional compound is described comprising the step of reacting a lactone or hydroxy carboxylic acid with a compound (A) comprising a carbamate or urea group or a group that can be converted to a carbamate or urea group, and an active hydrogen group capable of reacting with the hydroxy carboxylic acid or in a ring-opening reaction with a lactone. The compound thus prepared is useful in curable compositions.

Abstract: A method of forming a methylol urea prepolymer and a particle coated in with the prepolymer. The method involves providing a source of methylol urea and a source of aldehyde and reacting the urea and the aldehyde in the presence of an excess of urea to form the methylol urea prepolymer. The coated particle is preferably a controlled-release fertilizer particle. The particle is a substrate coated with a substantially uniform coating comprising a total nitrogen content ranging from about 39N to about 42N. The coating includes a low molecular weight methylene urea compounds.

Abstract: A 2- or 4-nitrobenzenesulfonamide is allowed to react with an alkali metal alkoxide to remove a nitrobenzenesulfonyl group to thereby obtain an amine corresponding to the amide. Furthermore, a method for producing an amine derivative by allowing the resulting amine without isolation to react with an activated, substituted oxycarbonyl compound or an activated acyl compound is provided. According to this method, a corresponding free amine and its substituted derivative can be produced easily and industrially advantageously from the 2- or 4-nitrobenzenesulfonamide without using a thiol compound.

Abstract: The present invention relates to blocked fluorine-containing polyisocyanates which have a fluorine content, calculated as F=19, of 1.0 to 20.0 wt. %, preferably 4.0 to 10.0 wt. %, and are suitable for preparing stoving coatings having a water- and soil-repellent surface, wherein the fluorine-containing polyisocyanates are based on the reaction product of aliphatic polyisocyanates or polyisocyanate mixtures having an NCO content of 10 to 25 wt. % and a functionality of at least 2.5 with monofunctional isocyanate blocking agents and a fluorinated monoalcohols wherein i) 75 to 95 equivalent-% of the isocyanate groups are reacted with isocyanate blocking agents, ii) 5 to 25 equivalent-% of the isocyanate groups are reacted with fluorinated monoalcohols and iii) the equivalents of i) and ii) add up to 100%.

Abstract: The present invention provides compounds and libraries of compounds having formula (I): 1

Abstract: The present invention is directed to a rheology control agent. The rheology control agent is used in a coating composition and is the reaction product of a first compound comprising a plurality of hydroxyl groups, of a lactone compound, and of a carbamate compound. The present invention is also directed to a coating composition including the rheology control agent and to a method of preparing the rheology control agent.

Abstract: The process disclosed herein satisfies the need in the art for an industrially viable oxidative carbonylation catalytic system, and is capable of producing carbamates at a significantly higher rate than those processes reported in journal and patent literature. This reaction process takes place via a reaction mechanism that does not involve drastic conditions. Specifically, the catalytic system of the present invention employs Group VIII metal catalysts and/or copper-based catalysts with halide promoters to produce carbamates through heterogeneous oxidative carbonylation at atmospheric pressure and relatively non-drastic temperatures in a gas-solid carbonylation process.

Abstract: The invention concerns a compound of formula (I) in which m is to 0 or 1 Iso is the (poly)isocyanate radical (after elimination of an isocyanate function); R10 is selected among: a negative charge; a hydrocarbon-based radical (i.e. a residue containing hydrogen and carbon atoms) having a carbon as it binding point [i.e. the atom carrying the open bond]; R11 is selected among a negative charge. The invention is applicable to organic synthesis.

Abstract: The invention relates to a process for preparing quinoline-substituted carbonate and carbamate compounds, which are important intermediates in the synthesis of 6-O-substituted macrolide antibiotics. The process employs metal-catalyzed coupling reactions to provide a carbonate or carbamate of formula (I) or (II) or a substrate that can be reduced to obtain the same.

Abstract: Phenylurethane compounds of the following general formula (1); asymmetric urea compounds of the following general formula (10) obtained from the phenylurethane compounds; barbituric acid derivatives of general formula (18) produced from the asymmetric urea compounds, which have specific substituents and are useful in diazo thermal recording materials; and diazo thermal recording materials containing the barbituric acid derivative.

Abstract: The present invention relates to novel felbamate derivatives and their use to treat neurological diseases such as epilepsy and to treat tissue damage resulting form ischemic events. The felbamate derivatives are modified to prevent the formation of metabolites that are believed responsible for the toxicity associated with felbamate therapy.

Abstract: This invention involves a carbamate functional polymer or oligomer made by reacting a cyclic carbonate with ammonia or a primary amine, then reacting the resulting hydroxycarbamate with a polyfunctional material containing groups reactive with hydroxyl groups to form a polyfunctional carbamate. The polymer formed is mixed with an aminoplast, coated on a substrate and cured to form a crosslinked coating.

Abstract: Methyl carbazate which is particularly pure and has a particularly low tendency toward discoloration is obtained from hydrazine and dimethyl carbonate if the two reactants are metered simultaneously into an initially introduced first solvent at from −20 to +30° C., the solvent and low-boiling components are then distilled off under reduced pressure, and then either a second solvent is added to the crude methyl carbazate present and this solvent is distilled off under reduced pressure or an inert gas is passed through the crude methyl carbazate present.

Abstract: Carbamate solutions are obtainable by reacting at least one alkanolamine with carbon dioxide in, as solvent, at least one organic compound having a molecular weight of from 60 to 600 and containing at least one hydroxyl group, wherein the carbamate contains at least 0.

Abstract: The present invention provides a compound according to the formula: CH2═C(R1)—C(O)—R6—NHCO2(CH2)p(CF2)q—O—((CF2)aCFXO)m(CF2)r—Z wherein each R1 is independently selected from —H, —CH3, —F and —Cl, wherein each R6 is independently selected from substituted or unsubstituted C1-C10 alkyl, cyclic alkyl, or aryl groups, wherein each a is independently selected from 0-3, wherein each X is independently selected from —F, —CF3 or —CF2CF3, wherein each p is independently selected from 1-4, each q is independently selected from 1-5, each r is independently selected from 1-5, each m is independently selected from 1-50, each Z is independently selected from —F and —(CH2)sOH, and each s is independently selected from 1-4. The present invention also provides for the use of this compound as a surfactant in highly fluorinated liquid solvents. Latexes of dispersed particles utilizing this surfactant are provided.

Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.

Abstract: A phosgene-free method for preparing a carbamate from a compound containing an amine group involves reacting the compound with an alkylating agent in the presence of carbon dioxide and cesium carbonate. A reaction can take place under standard pressure and temperature conditions and produces carbamates in a high yield with low by-product formation.

Abstract: The present invention provides non-steroidal compounds of Formula I, and prodrugs and pharmaceutically acceptable salts thereof, which are selective modulators (e.g., agonists, partial agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides processes for preparing these compounds.